Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 96

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 96
---
 the ordinary or conditional share capital increases or the introduction of a capital band may be challenged. •The NLS Common Shares are not listed in Switzerland, our home jurisdiction. As a result, the Swiss takeover regime does not apply. •U.S. shareholders may not be able to obtain judgments or enforce civil liabilities against NLS or its executive management or the NLS Board. •NLS’s status as a Swiss stock corporation means that its shareholders enjoy certain rights that may limit its flexibility to raise capital, issue dividends and otherwise manage ongoing capital needs. •Shareholders outside of the United States may not be able to exercise pre -emptiverights in future issuances of equity or other securities that are convertible into equity. •Following the closing of the Merger, NLS may lose its foreign private issuer status, which would then require it to comply with the domestic reporting requirements of the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act, and cause it to incur significant legal, accounting and other expenses. •Failure to consummate the Merger as currently contemplated or at all could adversely affect the price of NLS Common Shares or Kadimastem Ordinary Shares and the future business and financial results of NLS and Kadimastem. •The ownership interests of NLS’s and Kadimastem’s shareholders will be diluted by the consummation of the Merger, and NLS’s and Kadimastem’s shareholders will exercise less influence over management than they exercised before the Merger. •The interests of NLS’s and Kadimastem’s directors and executive officers include, among other things, the continued service as a director or executive officer of NLS following the Merger and certain rights to continuing indemnification and directors’ and officers’ liability insurance for Kadimastem directors and executive officers. There is a risk that these interests may influence the directors and executive officers to support the Merger. •The Merger is subject to the satisfaction or waiver of conditions that may not be satisfied or completed on a timely basis, if at all. Failure to consummate the Merger could adversely affect the future business and financial results of NLS. •NLS or Kadimastem may waive one or more of the conditions to the Merger without re -solicitingshareholder approval. 24 •The Merger may be completed even though material adverse changes subsequent to the announcement of the Merger, such as industry -widechanges or other events, may occur. •NLS will